Toll Free: 1-888-928-9744

Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 31 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Review, H1 2016', provides in depth analysis on Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1)
- The report reviews Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) Overview 6 Therapeutics Development 7 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Products under Development by Stage of Development 7 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Products under Development by Therapy Area 8 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Products under Development by Indication 9 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Pipeline Products Glance 10 Early Stage Products 10 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Products under Development by Companies 11 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Products under Development by Universities/Institutes 13 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Companies Involved in Therapeutics Development 20 Johnson & Johnson 20 Lead Pharma Holding B.V. 21 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Drug Profiles 22 CAS-001 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 CAS-003 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CAS-045 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 JNJ-35815208 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Agonize Estrogen Related Receptor Alpha for Cancer and Metabolic Disorders - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules to Agonize ERR-Alpha for Metabolic Disorders - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 SR-16388 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Steroid Hormone Receptor ERR1 (Estrogen Receptor-Like 1 or Estrogen-Related Receptor Alpha or ERR-Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or ESRRA or ERR1) - Dormant Projects 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Johnson & Johnson, H1 2016 20 Pipeline by Lead Pharma Holding B.V., H1 2016 21 Dormant Projects, H1 2016 29


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Mechanism of Actions, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify